Related references
Note: Only part of the references are listed.The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets
Damian Szklarczyk et al.
NUCLEIC ACIDS RESEARCH (2021)
Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine
Maria Rivera et al.
NEOPLASIA (2021)
Feasibility of Phosphoproteomics on Leftover Samples After RNA Extraction With Guanidinium Thiocyanate
Frank Rolfs et al.
MOLECULAR & CELLULAR PROTEOMICS (2021)
Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome
Mariette Labots et al.
CANCERS (2020)
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype
Barbara Lupo et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities
Suhas Vasaikar et al.
CELL (2019)
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases
Robin Beekhof et al.
MOLECULAR SYSTEMS BIOLOGY (2019)
A Curated Resource for Phosphosite- specific Signature Analysis
Karsten Krug et al.
MOLECULAR & CELLULAR PROTEOMICS (2019)
The PRIDE database and related tools and resources in 2019: improving support for quantification data
Yasset Perez-Riverol et al.
NUCLEIC ACIDS RESEARCH (2019)
KIF22 coordinates CAR and EGFR dynamics to promote cancer cell proliferation
Rosemary Pike et al.
SCIENCE SIGNALING (2018)
KIF22 coordinates CAR and EGFR dynamics to promote cancer cell proliferation
Rosemary Pike et al.
SCIENCE SIGNALING (2018)
Genenames.org: the HGNC and VGNC resources in 2017
Bethan Yates et al.
NUCLEIC ACIDS RESEARCH (2017)
Impact of phosphoproteomics in the translation of kinase-targeted therapies
Pedro Casado et al.
PROTEOMICS (2017)
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Ben Zhao et al.
ONCOTARGET (2017)
Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection
Mariette Labots et al.
JOURNAL OF PROTEOMICS (2017)
Colon Cancer, Version 1.2017 Clinical Practice Guidelines in Oncology
Al B. Benson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
The target landscape of clinical kinase drugs
Susan Klaeger et al.
SCIENCE (2017)
Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer
Claudio Isella et al.
NATURE COMMUNICATIONS (2017)
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
D. Arnold et al.
ANNALS OF ONCOLOGY (2017)
Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis
E. J. van Helden et al.
CANCER AND METASTASIS REVIEWS (2017)
EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer
Philip D. Dunne et al.
CLINICAL CANCER RESEARCH (2016)
Chemical Proteomics and Structural Biology Define EPHA2 Inhibition by Clinical Kinase Drugs
Stephanie Heinzlmeir et al.
ACS CHEMICAL BIOLOGY (2016)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Zuguang Gu et al.
BIOINFORMATICS (2016)
KIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer
Yi-Zhen Liu et al.
SCIENTIFIC REPORTS (2016)
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas
Simonetta M. Leto et al.
CLINICAL CANCER RESEARCH (2015)
SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer
J. Randolph Hecht et al.
CLINICAL COLORECTAL CANCER (2015)
Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition
Heiner Koch et al.
JOURNAL OF PROTEOME RESEARCH (2015)
Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines
Sander R. Piersma et al.
JOURNAL OF PROTEOMICS (2015)
Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomics
Johannes C. van der Mijn et al.
Journal of Proteomics (2015)
The genomic landscape of response to EGFR blockade in colorectal cancer
Andrea Bertotti et al.
NATURE (2015)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies
Eugenia R. Zanella et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
Shyam M. Kavuri et al.
CANCER DISCOVERY (2015)
PhosphoSitePlus, 2014: mutations, PTMs and recalibrations
Peter V. Hornbeck et al.
NUCLEIC ACIDS RESEARCH (2015)
PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
Lee S. Schwartzberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
Timothy J. Price et al.
LANCET ONCOLOGY (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
The Prognostic Role of Ephrin A2 and Endothelial Growth Factor Receptor Pathway Mediators in Patients With Advanced Colorectal Cancer Treated With Cetuximab
Alexios Strimpakos et al.
CLINICAL COLORECTAL CANCER (2013)
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Alberto Bardelli et al.
CANCER DISCOVERY (2013)
An accurate paired sample test for count data
Thang V. Pham et al.
BIOINFORMATICS (2012)
clusterMaker: a multi-algorithm clustering plugin for Cytoscape
John H. Morris et al.
BMC BIOINFORMATICS (2011)
Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations
Francesco Galimi et al.
CLINICAL CANCER RESEARCH (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
A Molecularly Annotated Platform of Patient-Derived Xenografts (Xenopatients) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Andrea Bertotti et al.
CANCER DISCOVERY (2011)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Loss of tight junction barrier function and its role in cancer metastasis
Tracey A. Martin et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2009)
Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-I receptor and insulin receptor
Mark J. Mulvihill et al.
FUTURE MEDICINAL CHEMISTRY (2009)
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
Joan M. Carboni et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines
Rossella Solmi et al.
BMC CANCER (2008)
Regulation of mitochondrial oxidative phosphorylation through cell signaling
Maik Huttemann et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Phosphopeptide enrichment by aliphatic hydroxy acid-modified metal oxide chromatography for nano-LC-MS/MS in proteomics applications
Naoyuki Sugiyama et al.
MOLECULAR & CELLULAR PROTEOMICS (2007)
BiNGO: a Cytoscape plugin to assess overrepresentation of Gene Ontology categories in Biological Networks
S Maere et al.
BIOINFORMATICS (2005)
Cytoscape: A software environment for integrated models of biomolecular interaction networks
P Shannon et al.
GENOME RESEARCH (2003)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)